Glucagon
Pre-clinicalCompleted 0 watching 0 views this week💤 Quiet
22
Development Stage
1
Pre-clinical2
Phase 13
Phase 24
Phase 35
ApprovedIndication / Disease
Non-Alcoholic Fatty Liver Disease
Conditions
Non-Alcoholic Fatty Liver Disease, Glucagon Resistance
Trial Timeline
Feb 8, 2021 → Dec 9, 2021
NCT ID
NCT04859322About Glucagon
Glucagon is a pre-clinical stage product being developed by Novo Nordisk for Non-Alcoholic Fatty Liver Disease. The current trial status is completed. This product is registered under clinical trial identifier NCT04859322. Target conditions include Non-Alcoholic Fatty Liver Disease, Glucagon Resistance.
Hype Score Breakdown
Clinical
5
Activity
2
Company
9
Novelty
2
Community
1
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT04859322 | Pre-clinical | Completed |
Competing Products
20 competing products in Non-Alcoholic Fatty Liver Disease